On 21 May 2026, the MHRA opened a consultation on a new Rare Disease Therapies Framework, with responses due by 30 July 2026. On paper this is a regulatory story. In practice, it is also a test of whether the UK can make ultra-rare drug development more investable for biotech, pharma and specialist research partners. That commercial angle matters. The draft is aimed at conditions affecting roughly one in 50,000 people or fewer in the UK, where small patient groups and patchy evidence have often made conventional development models hard to finance. For listed biotech watchers, it speaks to the conditions that decide where early science gets funded and where clinical work is based.

According to the MHRA, traditional rare disease programmes often take 10 to 12 years to reach marketing authorisation. For companies working on tiny patient populations, that sort of timeline can drain capital before a therapy gets close to revenue, especially when trial design, evidence standards and approval steps were built for larger studies. The proposed framework is trying to fix that mismatch with a more flexible, risk-proportionate route rather than another layer of guidance. It is designed to be technology-agnostic, so the same approach could apply across gene-based therapies, advanced therapy medicinal products, personalised medicines, digital-enabled products, new manufacturing methods and repurposed drugs.

The most commercially relevant idea is the proposed Investigational Marketing Authorisation, or IMA. Instead of treating clinical trial approval and marketing authorisation as two separate regulatory gates, the IMA would create a single route with rolling data submissions, modular review and earlier patient access where evidence is limited but persuasive, backed by structured post-authorisation evidence collection. For larger drugmakers, that could make very small indications easier to assess as part of a wider portfolio. For smaller developers, spin-outs and academics, the appeal is earlier regulatory feedback and a clearer sense of what evidence the MHRA is prepared to accept before more capital is committed.

The draft also gives the MHRA room to accept adaptive trial designs, including basket and umbrella studies, alongside real-world evidence where standard endpoints are unrealistic. It also signals openness to surrogate or patient-relevant endpoints, computational modelling, digital twins and non-animal methods when the science supports it. That does not remove risk, and it should not. But it could reduce some of the wasted time that comes from forcing rare disease programmes through a template built for far larger markets. For investors, the key question is whether this produces fewer dead ends between early clinical promise and a reimbursable product.

The UK already has some of the pieces that matter here: a strong university base, a national genomics system and NHS data that can support recruitment, follow-up and evidence generation. The MHRA is clearly trying to turn those strengths into a more coherent offer for companies deciding where to run trials, place manufacturing and build rare disease platforms. That is why this consultation matters beyond Whitehall. If the final framework is workable, it could make the UK more attractive for specialist CROs, manufacturing partners and licensing deals in areas that have often looked too small or too slow under standard development economics.

There is also an important signal in who has helped shape the draft. The Rare Disease Consortium brings together the MHRA, NICE, the Department of Health and Social Care, NHS England, patient groups, academic centres and a long list of industry names including LifeArc, Cell and Gene Therapy Catapult, AstraZeneca’s Alexion unit, Biogen, Alnylam, Vertex, BioMarin and Syncona. NICE’s involvement matters in particular. Helen Knight, NICE’s Director of Medicines Evaluation, has indicated that the proposal could sit alongside NICE’s existing approach of allowing promising medicines into NHS use while further evidence is gathered, which is one of the clearest signs yet that the policy is being built with both approval and payer scrutiny in mind.

There is still a great deal to settle. The consultation asks industry to comment on IMA eligibility, the use of real-world evidence, scientific advice and how the new route should sit alongside orphan designation and the Innovative Licensing and Access Pathway. Those details will decide whether the framework becomes a genuine advantage or just a more complicated set of forms. The MHRA says it will run general sessions over the summer while responses are considered. For founders, investors and business development teams, the message is straightforward: this is not only a consultation on rare disease regulation; it is a consultation on UK life sciences competitiveness. If ministers want more trial activity and more capital pointed at ultra-rare therapies, the final version will need to be usable as well as ambitious.